Program
fluciclovine F-18
Also written as “18F fluciclovine”, “fluciclovine (18F)” and “18F-fluciclovine PET CT”.
Its studies are mostly in Prostatic Neoplasms · Brain Neoplasms, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bracco | 41 open or running | phase 4since Apr 22, 2026 | Jan 15, 2016 | Dec 31, 2027phase 4 · NCT07569926 |
| GE Healthcare | 10 open or running | phase 2since Aug 5, 2010 | Aug 5, 2010 | none ahead |
Also a collaborator on its studies: Precision For Medicine, IND 2 Results and Syne Qua Non.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 5, 2010First study: phase 2 study in Prostatic NeoplasmsNew to GE HealthcareGE Healthcare · NCT01176513 · 25 enrolled · United States
- Jan 15, 2016Bracco’s first study: phase 3 study in Prostatic NeoplasmsNew to BraccoBracco · NCT02680041 · 221 enrolled · United States
- May 27, 2020Phase 2 study in Brain NeoplasmsBracco · NCT04410367 · 23 enrolled · United States
- May 27, 2020Phase 3 study in Brain NeoplasmsBracco · NCT04410133 · 151 enrolled · United States
- Apr 22, 2026Phase 4 study in Prostatic NeoplasmsBracco · NCT07569926 · 142 planned · United States
Ahead
- Dec 31, 2027Primary completion: phase 4 study in Prostatic NeoplasmsBracco · NCT07569926
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07569926Prostatic Neoplasms · United States | 4 | Recruiting | Bracco | Dec 31, 2027 | 142 |
| NCT04410367Brain Neoplasms · United States | 2 | Completed | Bracco | Dec 31, 2021 | 23 |
| NCT04410133Brain Neoplasms · United States | 3 | Completed | Bracco | Jun 5, 2023 | 151 |
| NCT02680041Prostatic Neoplasms · United States | 3 | Completed | Bracco | Nov 1, 2017 | 221 |
| NCT01176513Prostatic Neoplasms · United States | 2 | Terminated | GE Healthcare | Mar 2012 | 25 |
How it is read
Names in the registry
- “18F fluciclovine”, 2 entries
- “fluciclovine (18F)”, 1 entry
- “18F-fluciclovine PET CT”, 1 entry
- “GE-148 (18F)”, 1 entry
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 3 studies
- Brain Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.